The product prototype, designated “P3L” by the technology owner Philip Morris International, mixes nicotine with lactic acid to produce an inhalable nicotine salt aerosol with faster absorption rates than traditional nicotine replacement therapies. The d
The post Christchurch Clinical Studies Trust Announces Completion of a Clinical Study on Innovative Nicotine-Containing Product appeared first on The Center.
Smoking Cessation Feeds
http://ift.tt/1PDRweS September 26, 2016 at 06:03AM
No comments:
Post a Comment